Sistema de Salut de Catalunya
Institut Català de la Salut
[Bartels M] Department of Medical Oncology, Praxis für Onkologie Mönchengladbach, Mönchengladbach, Germany. [Chibaudel B] Department of Medical Oncology, Hôpital Franco-Britannique-Fondation Cognacq-Jay, Cancérologie ParisOuest, Levallois-Perret, France. [Dienstmann R] Oncology Data Science (ODysSey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. University of Vic-Central University of Catalonia, Vic, Spain. Oncoclínicas, São Paulo, Brazil. [Lehtiö J] Science for Life Laboratory and Karolinska Comprehensive Cancer Center, Department of Oncology and Pathology, Karolinska Institutet, Solna, Sweden. [Piccolo A] Pathology Unit 2, Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. [Michielin O] Department of Oncology and the Precision Oncology Service, Geneva University Hospital, Geneva, Switzerland
Vall d'Hebron Barcelona Hospital Campus
2025-02-17T13:41:51Z
2025-02-17T13:41:51Z
2024-08
Molecular tumor board; Molecularly guided therapy; Precision oncology
Comité de tumores moleculares; Terapia guiada molecularmente; Oncología de precisión
Comité de tumors moleculars; Teràpia guiada molecularment; Oncologia de precisió
The increasing volume of information for cancer care, and the evolution of molecularly guided therapies, have increased the need for molecular tumor boards (MTBs), which can integrate such data into personalized treatment plans to improve patient outcomes. However, recommendations for improving the sustainability of MTBs are lacking. A diverse committee of MTB experts was assembled (February-March 2023), with extensive experience in sustainability in healthcare ecosystems. The aim was to identify MTB-related hurdles throughout the patient journey and develop a general framework for MTBs to operate on larger scales locally, nationally, and internationally. The committee identified ten key pillars for sustainable and scalable MTBs, including technical solutions for data integration and visualization, interoperability, learning loops, clinical trial access, legal considerations, criteria for patient testing, decision standardization, making MTBs official bodies for treatment decisions, local leaders, and international networks. The need for scalable frameworks at academic and community levels was recognized, along with integrating MTBs into national health systems to enhance sustainability and ensure optimal treatment decisions. Irrespective of the health ecosystem, the sustainability and scalability of MTBs are essential. Our framework provides guidelines to address this and to help MTBs evolve towards integrated, essential components of the oncology healthcare system.
The APC was funded by F. Hoffmann-La Roche Ltd.
Article
Published version
English
Càncer - Tractament; Medicina personalitzada; Comissions; DISEASES::Neoplasms; Other subheadings::Other subheadings::/therapy; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Precision Medicine; DISCIPLINES AND OCCUPATIONS::Health Occupations::Medicine::Internal Medicine::Medical Oncology; Other subheadings::Other subheadings::/organization & administration; ENFERMEDADES::neoplasias; Otros calificadores::Otros calificadores::/terapia; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::medicina de precisión; DISCIPLINAS Y OCUPACIONES::profesiones sanitarias::medicina::medicina interna::oncología médica; Otros calificadores::Otros calificadores::/organización & administración
Cancers;16(16)
https://doi.org/10.3390/cancers16162888
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
